Gsk (GSK) Cash from Financing Activities (2009 - 2026)

Gsk's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $366.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 66.07% year-over-year to $366.7 million; the TTM figure through Mar 2026 stood at -$4.0 billion (up 1.34% YoY), while the FY2025 annual figure was -$4.9 billion, up 19.57% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $366.7 million, up from -$2.0 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $1.1 billion in Q1 2025, with the low at -$6.6 billion in Q4 2022.
• The 5-year median for Cash from Financing Activities is -$1.3 billion (2024), against an average of -$1.6 billion.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 852.69% in 2024, then surged 180.37% in 2025.
• Gsk's Cash from Financing Activities stood at -$6.6 billion in 2022, then surged by 94.57% to -$356.2 million in 2023, then plunged by 852.69% to -$3.4 billion in 2024, then soared by 40.66% to -$2.0 billion in 2025, then surged by 118.21% to $366.7 million in 2026.
• Business Quant data shows GSK's Cash from Financing Activities at $366.7 million in Q1 2026, -$2.0 billion in Q4 2025, and $1.1 billion in Q1 2025.